Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2

Cerebral edema following chimeric antigen receptor (CAR) T-cell therapy can be fatal. ZUMA-2 is a pivotal phase 2, multicenter study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in relapsed/refractory mantle cell lymphoma. We describe a 65-year-old patient in ZUMA-2 who developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Michael, Jain, Preetesh, Chi, T Linda, Chen, Sheree E, Heimberger, Amy, Weathers, Shiao-Pei, Zheng, Lianqing, Rao, Arati V, Rossi, John M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570235/
https://www.ncbi.nlm.nih.gov/pubmed/33067318
http://dx.doi.org/10.1136/jitc-2020-001114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570235/
https://www.ncbi.nlm.nih.gov/pubmed/33067318
http://dx.doi.org/10.1136/jitc-2020-001114

Ejemplares similares